rutecarpine has been researched along with Atherogenesis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Han, X; Jiang, X; Li, N; Li, Y; Liu, C; Luo, J; Si, S; Wang, X; Xu, Y; Zuo, X | 1 |
| Feng, T; He, X; Hong, B; Jiang, JD; Lai, F; Li, N; Li, Y; Liu, C; Liu, J; Liu, Q; Si, S; Wang, X; Wu, Y; Xu, Y; Zhang, M; Zhu, N | 1 |
| Fu, YQ; He, M; Huang, QR; Liu, Y; Luo, D; Peng, WJ; Wu, YS; Yan, H; Yu, YR | 1 |
3 other study(ies) available for rutecarpine and Atherogenesis
| Article | Year |
|---|---|
Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasome-related inflammation and modulating cholesterol transport.
Topics: Animals; Atherosclerosis; Biological Transport, Active; Cholesterol; Indole Alkaloids; Inflammasomes; Inflammation; Macrophages; Mice; Mice, Knockout, ApoE; NLR Family, Pyrin Domain-Containing 3 Protein; Quinazolines | 2020 |
Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCT.
Topics: Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; Indole Alkaloids; Liver; Mice; Mice, Knockout; Quinazolines; RAW 264.7 Cells; Scavenger Receptors, Class B | 2014 |
Rutaecarpine Reverses the Altered Connexin Expression Pattern Induced by Oxidized Low-density Lipoprotein in Monocytes.
Topics: Adenosine Triphosphate; Atherosclerosis; Cells, Cultured; Connexins; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Indole Alkaloids; Lipoproteins, LDL; Monocytes; Quinazolines; Time Factors | 2016 |